A recent publication in European Urology suggests that there is overwhelming evidence that using a low-intensity shock treatment (LI-ESWT) can positively impact patients with mild-to-moderate erectile dysfunction. This is a promising form of therapy that requires more research. For now drugs such as sildenafil (Viagra) and tadalafil (Cialis) remain the mainstay of therapy followed by the […]
Living With Diabetes, Research
Today the results of 2 important studies in Type 2 diabetes presented at the annual American Diabetes Association meeting in New Orleans this week were published in the prestigious New England Journal of Medicine. The LEADER study examined the outcomes of 9,340 patients with Type 2 diabetes followed for four years. All took standard diabetes […]
In a recent Environmental Health journal, Joseph G. Allen, et al. published the results of a review of data on thyroid problems and blood concentrations of four different types of polybrominated diphenyl ethers (PBDEs) in women interviewed in 2003 and 2004. BCDiabetes medical director, Dr. Tom Elliott discusses the impact this particular research could impact clinical care. The recent […]
A recent study published in the journal diabetes from the group of Dr. Michael Christie at the University of Lincoln in England has identified a fifth element involved in the immune system’s destruction of beta cell (the cells that produce & secrete insulin) that cause Type 1 diabetes. Other well-understood targets include insulin and glutamade […]
Living With Diabetes, News & Media, Research
A report on Reuters Health yesterday shared that Type 1 diabetes is tied to risk for a wide range of cancers and that, specifically, “people with type 1 diabetes are more likely than the general population to develop cancers of gastric organs and the kidneys, as well as endometrium and ovaries for women, according to […]
In September BC Diabetes blogged on the astounding outcome of the EMPA-REG OUTCOME® study indicating a 32% reduction in all- cause mortality in high risk individuals with Type 2 diabetes randomized to empagliflozin 10 or 25 milligrams compared to placebo. This report on the presentation of the renal outcomes of the same study from San Diego last week. It […]
Empagliflozin “Jardiance” is the third member of the SGLT2 inhibitor class to be marketed in Canada. Like the other two members of the class (canagliflozin “Invokana” and dapagliflozin “Forxiga”) it lowers blood sugar and weight by causing wasting of sugar/glucose in the urine. This results in increased urine volumes in all patients and a tripling […]
It is with great excitement that we introduce our new diabetes clinic and research facility. This summer we moved from the Gordon and Leslie Diamond Health Care Centre and Vancouver General Hospital to a new customized facility located on the 4th floor at 210 West Broadway. Yes, the entire floor! Welcome. “The new space offers much […]
We are very excited about this made-in-BC research to help us find out if a drug will be beneficial for those taking it or whether it might make them ill before ever taking the drug. From Dr. Tom Elliott: “A new class of medication for diabetes known as GLP-1 agents have been on the Canadian market […]
We are very happy to announce that we have been added to a prestigious roster or institutions and organizations from across North America. This study is examining how a drug might help prevent kidney disease in people with Type 1 diabetes. To hear from the principal investigators, please click here to watch a brief video […]
Clinical Patient Feedback Form
